ClinicalTrials.gg
WithdrawnNCT01630967Updated Oct 1, 2026

Efficacy Study of Switching to a Lutenizing Hormone-releasing Hormone (LHRH) Antagonist From a LHRH Agonist to Treat Progressive Castrate Resistant Prostate Cancer (CRPC)

A Phase 2 interventional study of Degarelix in Prostate Neoplasm, sponsored by British Columbia Cancer Agency. Withdrawn at 1 site in Canada. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by British Columbia Cancer Agency · Phase 2, Interventional, and Treatment

How we know

Why this study was withdrawn
Site did not proceed with this study
Updated Oct 1, 2026Now WithdrawnEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 64 studies testing degarelix in Prostatic Neoplasms — 3 open to participants now, 5 under way, 2 of them phase 3. degarelix · Prostatic Neoplasms.

Enrollment
61st of 64
0 · median 127
Started
2012
with 6 others
Phase 2
27 of 64
2 open now
Registered
37th of 64
by date
Lead sponsor
2 of 64
British Columbia Cancer Agency

Among the 64 studies testing degarelix in Prostatic Neoplasms, this one is the 61st largest by enrollment, is one of 7 that started in 2012, is one of 27 in phase 2, and was the 37th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

3 of the 64 studies testing degarelix in Prostatic Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About degarelix

degarelix: first FDA approval 2008 (FIRMAGON), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies testing degarelix in Prostatic Neoplasms, or all of them as a file.
02

Study summary

Men with castrate resistant prostate cancer who are switched from a luteinizing hormone-releasing hormone (LHRH) antagonists from a LHRH agonist will experience a fall in prostate-specific antigen (PSA).

Read the detailed description

To determine the proportion of patients with castrate resistant Prostate Cancer who have a PSA decline of ≥50% from baseline PSA when switched from an LHRH agonist to an LHRH antagonist.

03

Conditions studied

  • Prostate Neoplasm

Browse trials for

Keywords

  • castrate resistance
  • PSA progression
  • LHRH antagonism
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed adenocarcinoma of the prostate
  • currently receiving LHRH agonist
  • Anti-androgen oral therapy is permitted but will be discontinued upon enrollment
  • PSA > 2 ng/ml
  • rising PSA despite LHRH agonist
  • patients may or may not have clinical evidence off . If metastases are present, they must be asymptomatic and in bone or lymph node only
  • Prior chemotherapy allowed
  • performance status 0-1

Exclusion criteria

Exclusion Criteria:

  • Patients with a history of other active , except: adequately treated non-melanoma skin cancer, superficial bladder cancer, or other solid tumours curatively treated with no evidence of disease for ≥ 3 years.
  • Other serious illness, psychiatric or medical condition that would not permit the patient to be managed according to the protocol including: i)Significant cardiovascular condition including but not limited to: uncontrolled hypertension, unstable angina, significant congestive heart failure or myocardial infarction, deep venous thrombosis, pulmonary embolus or cerebrovascular attack within the last 6 months. ii) History of significant neurological disorder that would impair the ability to obtain consent
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Degarelix

    Degarelix 240mg subcutaneously loading dose, then 80mg sc every month until disease progression.

    Drug: Degarelix

Interventions

  • Standard dosing and schedule for administration of degarelix will be used. 240mg s.c. loading dose, 80mg s.c. monthly maintenance dose.

    Also known as: Firmagon

06

What researchers measure

Primary outcomes

  1. 50% fall in PSA

    Proportion of patients with castrate resistant prostate cancer (CRPC) who have a PSA decline of ≥50% from baseline when switched from an LHRH agonist to an LHRH antagonist

    Time frame: 8 weekly

Secondary outcomes

  1. Luteinizing hormone (LH)

    Circulating androgen and pituitary hormones will be measured during the course of the study (8 weekly).

    Time frame: 8 weekly

  2. Follicle stimulating hormone (FSH)

    Circulating androgen and pituitary hormones will be measured during the course of the study (8 weekly).

    Time frame: 8 weekly

  3. Testosterone (TT)

    Circulating androgen and pituitary hormones will be measured during the course of the study (8 weekly).

    Time frame: 8 weekly

  4. dehydroepiandrosterone (DHEA)

    Circulating androgen and pituitary hormones will be measured during the course of the study (8 weekly).

    Time frame: 8 weekly

  5. dehydroepiandrosterone-sulfate (DHEA-S)

    Circulating androgen and pituitary hormones will be measured during the course of the study (8 weekly).

    Time frame: 8 weekly

  6. androstenedione (AED)

    Circulating androgen and pituitary hormones will be measured during the course of the study (8 weekly).

    Time frame: 8 weekly

  7. dihydrotestosterone (DHT)

    Circulating androgen and pituitary hormones will be measured during the course of the study (8 weekly).

    Time frame: 8 weekly

07

Study locations

1 site
  • British Columbia Cancer Agency
    Vancouver, British Columbia V5Z4E6, Canada
08

References and documents

Publications

  • Crawford ED, Tombal B, Miller K, Boccon-Gibod L, Schroder F, Shore N, Moul JW, Jensen JK, Olesen TK, Persson BE. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. J Urol. 2011 Sep;186(3):889-97. doi: 10.1016/j.juro.2011.04.083. Epub 2011 Jul 23. PubMed 21788033 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2012; primary completion for Dec 2013, 16 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2012
First posted
Jun 28, 2012
StartEst.
Aug 2012
Primary completionEst.
Dec 2013
CompletionEst.
Dec 2013
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Withdrawn Site did not proceed with this study
changed Oct 1, 2026
Enrollment
40 (estimated)→0 (actual)
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    Status unknown→Withdrawn
    Why stopped Site did not proceed with this study
    Enrollment 40 (estimated)→0 (actual)
    + 3 other changes: date precision, contact details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT01630967
Responsible party
Kim Chi (Associate Professor of Medicine, University of British Columbia, British Columbia Cancer Agency) — Principal investigator
First posted
Jun 28, 2012
Start date
Aug 2012 (estimated)
Primary completion
Dec 2013 (estimated)
Completion
Dec 2013 (estimated)
Last update
Oct 1, 2026

Study contacts

Kim N Chi, MD
principal investigator · British Columbia Cancer Agency, Univeristy of British Columbia

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Degarelix

Start the discussion